SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Molina Healthcare, Inc., Esperion Therapeutics, Inc., PPG Industries, Inc., Prothena Corporation, and Fluor Corporation

Tuesday, 19. June 2018 22:00

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Molina Healthcare, Inc. (NYSE:MOH)
Lead Plaintiff Deadline: June 29, 2018         
Class Period: October 31, 2014 and August 2, 2017

The complaint alleges that Molina's administrative infrastructure was never designed to handle the size and complexity of its rapid growth strategy; and it failed to remediate systemic issues and costly disruptions with critical administrative infrastructure functions, including provider payment and utilization management.

Get additional information:

Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Lead Plaintiff Deadline: July 6, 2018
Class Period: February 22, 2017 and May 1, 2018

The complaint alleges that Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times.

Get additional information:

PPG Industries, Inc. (NYSE:PPG)
Lead Plaintiff Deadline: July 19, 2018          
Class Period: April 24, 2017 and May 10, 2018

The complaint alleges that PPG’s consolidated financial statements for the year ended December 31, 2017 and quarterly financial statements for 2017 contained improper accounting entries and could no longer be relied upon; PPG failed to maintain adequate internal controls; and as a result, defendants’ public statements were materially false and misleading at all relevant times.

Get additional information:

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. To obtain additional information, contact Vincent Wong, Esq. either via email, by telephone at 212.425.1140, or visit the websites provided.

Prothena Corporation (NASDAQ:PRTA)
Lead Plaintiff Deadline: July 16, 2018          
Class Period: October 15, 2015 and April 20, 2018

The complaint alleges that Prothena issued materially false and misleading statements and/or failed to disclose that: the relevant trial data showed that Prothena’s antibody NEOD001, designed to treat amyloid light chain amyloidosis (“AL amyloidosis”), was not an effective treatment; the Company made misleading comparisons of NEOD001’s “best response” rates against certain prior studies; and the Company touted Prothena’s ongoing Phase 1/2 study of NEOD001 as providing a strong basis for late-stage Phase 2b and Phase 3 studies of NEOD001, even though the full Phase 1/2 study data demonstrated that NEOD001 was not an effective treatment.

Get additional information:

Fluor Corporation (NYSE:FLR)
Lead Plaintiff Deadline: July 24, 2018          
Class Period: August 14, 2013 and May 3, 2018

The complaint alleges that Fluor’s bidding process for projects related to the construction of gas-fired power generation facilities was flawed; Fluor had improperly estimated the gas-fire projects; as a result, Fluor would face craft productivity issues, equipment issues and other execution issues; Fluor would incur multiple charges impacting quarterly results; and Fluor would ultimately decide to discontinue the pursuit of the gas-fired power market.

Get additional information:

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880

Primary Logo

Related Links: 
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.